This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in Store for IDEXX Laboratories (IDXX) in Q1 Earnings?
by Zacks Equity Research
IDEXX (IDXX) first-quarter top line is expected to have benefited from strength in CAG and LPD businesses.
Thermo Fisher (TMO) to Report Q1 Earnings: WIll It Beat?
by Zacks Equity Research
Fewer hospital visits on growing new cases might have once again impacted the level of routine diagnostics testing activity for Thermo Fisher (TMO) in Q1.
New Launches in Breast Health to Aid Hologic (HOLX) Q2 Earnings
by Zacks Equity Research
Strength in Molecular Diagnostics business is likely to have continued to aid Hologic's (HOLX) performance in the second quarter of fiscal 2021.
Hologic (HOLX) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Hologic (HOLX) is likely to have gained during fiscal second-quarter 2021 on the back of robust performances of its business arms despite coronavirus-led economic doldrums.
Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Owens & Minor (OMI) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Owens & Minor (OMI) closed at $38.18, marking a +0.77% move from the previous day.
Top Ranked Growth Stocks to Buy for April 22nd
by Zacks Equity Research
BSET, OMI, and BCC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on April 22, 2021
Align Technology (ALGN) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Align Technology (ALGN) is expected to have gained from robust Invisalign aligners and iTero scanners shipment volume in Q1.
Quest Diagnostics (DGX) Q1 Earnings Miss, Base Recovery Strong
by Zacks Equity Research
The updated first-half 2021 outlook by Quest Diagnostics (DGX) looks impressive given its raised revenue and operating cash flow expectations.
Enhance Your Portfolio With These 6 Low Price-to-Book Stocks
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects
Illumina (ILMN) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Illumina (ILMN) is likely to have gained during the first quarter on the back of robust performance of the sequencing consumable segment.
Unlock the Value of Your Portfolio With 4 Low P/CF Stocks
by Sumit Singh
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. Goldman Sachs (GS), Owens & Minor (OMI), Boise Cascade (BCC) and Vishay Intertechnology (VSH) boast low P/CF ratio.
Zacks Industry Outlook Highlights: MedTech, including Natus Medical, Owens & Minor, Penumbra, Apollo Medical and ENDRA Life Sciences
by Zacks Equity Research
Zacks Industry Outlook Highlights: MedTech, including Natus Medical, Owens & Minor, Penumbra, Apollo Medical and ENDRA Life Sciences
5 MedTech Outperformers With Nearly 40% or More Gain in 2021
by Debanjana Dey
Here are a few MedTech stocks, Natus Medical (NTUS), Owens & Minor (OMI), ENDRA Life Sciences (NDRA), Penumbra (PEN), Apollo Medical (AMEH), which might be prudent investment choices now.
Owens & Minor (OMI) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Owens & Minor (OMI) closed at $38.22 in the latest trading session, marking a +1.76% move from the prior day.
Why Owens & Minor (OMI) Could Beat Earnings Estimates Again
by Zacks Equity Research
Owens & Minor (OMI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Thermo Fisher (TMO) Gets EUA for Amplitude/TaqPath COVID-19 Kit
by Zacks Equity Research
Thermo Fisher's (TMO) Amplitude Solution is likely to allow clinical and public health laboratories to process up to 8,000 samples in a single day with the help of minimum workforce.
Thermo Fisher (TMO) Rides on End Markets as Pandemic Rages On
by Zacks Equity Research
In diagnostics and healthcare, Thermo Fisher (TMO) is experiencing high demand for COVID-19 testing and manages to record 200% growth.
Medtronic's (MDT) GI Genius Module Gets FDA De Novo Clearance
by Zacks Equity Research
Medtronic's (MDT) GI Genius Module is the only commercially available computer-aided detection system which uses artificial intelligence to identify colorectal polyploid.
Here's Why You Should Hold on to Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) owing to its progress with its three-legged strategic, which is driving growth and an impressive 2025 roadmap.
Cardiovascular Systems (CSII) Inks Deal to Enhance Patient Care
by Zacks Equity Research
Cardiovascular Systems' (CSII) investment in CarePICS will advance patient access to the suitable treatment at the right time, thereby leading to improved care and reduced amputations.
Owens & Minor (OMI) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Owens & Minor (OMI) closed at $37.59 in the latest trading session, marking a +0.45% move from the prior day.
3 GARP MedTech Stocks to Snap Up Despite Pandemic Woes
by Trina Mukherjee
Here we look at three stocks, OMI, HOLX and QGEN, that investors can add to their watchlist backed by robust long-term prospects.
CVS Health (CVS) Extends COVID-19 Antibody Testing Nationwide
by Zacks Equity Research
CVS Health's (CVS) antibody test detects for previous infection to COVID-19 and provides results within 15 minutes.
NuVasive's (NUVA) Simply Cervical Artificial Disc Gets FDA Nod
by Zacks Equity Research
NuVasive's (NUVA) Simplify Disc demonstrated an overall clinical success rate nearly 10% higher than the anterior cervical discectomy and fusion.